Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 7/20 | 0.70 |
| ▸ | DRD4 | P21917 | 5/20 | 0.70 |
| ▸ | DRD2 | P14416 | 5/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | PRCP | P42785 | 1/20 | 0.70 |
| ▸ | EBP | Q15125 | 1/20 | 0.70 |
| ▸ | HTR1A | P08908 | 3/20 | 0.58 |
| ▸ | DRD1 | P21728 | 3/20 | 0.58 |
| ▸ | DRD5 | P21918 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7354726 | 1.00 | DRD3 (0.70) | DRD3DRD4DRD2SIGMAR1NFKB1 | |
| SCHEMBL29567496 | 1.00 | DRD3 (0.70) | DRD3DRD4DRD2SIGMAR1NFKB1 | |
| Iodide SCHEMBL29566919 | 0.98 | DRD3 (0.68) | DRD3DRD4DRD2SIGMAR1NFKB1 | |
| SCHEMBL11269553 | 0.83 | DRD3 (0.50) | DRD3DRD4DRD2SIGMAR1NFKB1 | |
| SCHEMBL29786277 | 0.83 | DRD3 (0.58) | DRD3DRD4DRD2SIGMAR1NFKB1 | |
| SCHEMBL23123632 | 0.83 | DRD3 (0.58) | DRD3DRD4DRD2SIGMAR1NFKB1 | |
| SCHEMBL11888476 | 0.83 | DRD3 (0.69) | DRD3DRD4DRD2SIGMAR1NFKB1 | |
| SCHEMBL19122810 | 0.83 | DRD3 (0.69) | DRD3DRD4DRD2SIGMAR1NFKB1 | |
| Preclamol SCHEMBL872804 | 0.82 | DRD3 (1.00) | DRD3DRD4DRD2SIGMAR1NFKB1 | |
| Preclamol SCHEMBL29414104 | 0.82 | DRD3 (1.00) | DRD3DRD4DRD2SIGMAR1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | DRD3 4541/4885DRD4 4670/4885DRD2 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.